Sienna Biopharmaceuticals, Inc.’s $20 Million Common Stock Offering

Davis Polk advised the joint book-running managers in connection with a $20 million SEC-registered common stock offering by Sienna Biopharmaceuticals, Inc. The common stock is listed…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Ambrogio Visconti

This content is for Standard 1 Year members only.
Login Join Now